Navigation Links
Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Date:11/12/2009

BASKING RIDGE, N.J., Nov. 12 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, November 17 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. This conference is well attended and will include several hundred institutional investors with more than one hundred healthcare management teams presenting.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BOTHELL, Wash. , July 31, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s second quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
(Date:7/31/2014)... July 31, 2014 The Kidney Cancer Association ... its monthly news magazine, Kidney Cancer News. , Bill ... on a website maintained by an international news organization. When ... increase in viewers.” , This month’s program highlights news of ... analyzed in a recent study. Kidney Cancer News also ...
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... its potential as a near-term generator of energy efficiencies ... Phillips, director of the Physical, Chemical, and Nano Sciences ... annual meeting. The meeting runs Feb. 18-22 in San ... that solid-state lighting can better utilize existing energy sources ...
... ... ... ... ...
... , MONTREAL , Feb. ... and advanced chemicals technology company, today announced that Mr. ... Vice-President and Chief Financial Officer. , Mr. Ouimet brings ... of executives, with substantial experience in corporate strategy, corporate ...
Cached Biology Technology:CHMP Adopts Negative Opinion for ZEFTERA(TM) 2CHMP Adopts Negative Opinion for ZEFTERA(TM) 3Enerkem appoints new Chief Financial Officer 2
(Date:7/30/2014)... regulate its genes, and adapt to changes in its ... regulation taking place in the truffle, is published in ... illustrates how the truffle deals with its complex genome,s ... may shed light on how traits like aroma and ... known as Prigord truffles, have a syrupy sweet flavor ...
(Date:7/30/2014)... and tended her eggs until they hatched 4.5 years ... in the open-access journal PLOS ONE by ... colleagues. , Octopuses typically have a single reproductive period ... care of their fertilized eggs until they hatch. Shallow-water ... 3 months, but little is known about the brooding ...
(Date:7/30/2014)... Scientists studying the potential effects of climate change ... focusing on the wrong factors, according to a ... Wildlife Conservation Society, University of Queensland, and other ... conservation science is missing the point when it ... majority of climate change scientists focus on the ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Deep-sea octopus has longest-known egg-brooding period 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... Evolutionary biologist Harmit Singh Malik, Ph.D., of Fred Hutchinson ... the Lupus Research Institute to study the potential role ... autoimmune disease. , Malik and colleagues want to find ... autoimmunity., "We want to determine whether autoimmunity when ...
... Parkinson,s and Alzheimer,s is set to take a step ... analysis using automated 3D microscopy. An initiative ... the Eskitis Institute for Cellular and Molecular Biology, the ... of cells as complex as nerve cells in the ...
... A new study led by the University of North ... starting at age 6 months in high-risk infants who later ... autism. "It,s a promising finding," said Jason J. Wolff, ... at UNC,s Carolina Institute for Developmental Disabilities (CIDD). "At this ...
Cached Biology News:Did an evolutionary arms race cause lupus? Biologist Harmit Malik receives grant to try and find out 2Brain-imaging differences evident at 6 months in infants who develop autism 2
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
... WesternBreeze Immunodetection Kits are designed for ... on nitrocellulose or PVDF membranes. Since ... membranes and primary antibodies), the WesternBreeze ... optimizing your protocol and getting your ...
... Monoclonal to L1 Cell Adhesion Molecule ... located in Xq28, is involved in three ... aqueduct of Sylvius); 2) MASA (mental retardation, ... SPG1 (spastic paraplegia). Immunogen: ...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: